Thirteen AACR Members Elected to the Institute of Medicine
PHILADELPHIA — The American Association for Cancer Research congratulates 13 of its members who are among 65 new members and five foreign associates elected to the Institute of Medicine (IOM). Considered among the highest honors in the fields of health and medicine, election to the IOM is granted to individuals who have demonstrated extraordinary professional achievement and commitment to service in the fields of health and medicine.
“We are thrilled that the Institute of Medicine is bestowing this great honor upon 13 of our prominent members,” said Margaret Foti, Ph.D., M.D. (h.c.), CEO of the American Association for Cancer Research (AACR). “The new inductees are leaders in cancer science and medicine who have made an enormous impact on our ability to prevent, diagnose and treat cancer. This is a great tribute to their lifelong dedication to cancer research.”
The AACR members elected to the IOM are:
Frederick W. Alt, Ph.D., investigator at Howard Hughes Medical Institute, Charles A. Janeway professor of pediatrics and professor of genetics at Harvard Medical School, and president of the Immune Disease Institute and director of the program in cellular and molecular medicine at Children’s Hospital Boston;
Karen H. Antman, M.D., provost at Boston University Medical Campus and dean of Boston University School of Medicine;
Martin J. Blaser, M.D., Frederick H. King professor of internal medicine, chair of the department of medicine, and professor of microbiology at New York University School of Medicine;
Carlo M. Croce, M.D., John W. Wolfe chair in human cancer genetics, chair of the department of molecular virology, immunology, and medical genetics, and director of the Institute of Genetics at The Ohio State University Medical Center in Columbus, Ohio;
George Q. Daley, M.D., Ph.D., investigator at Howard Hughes Medical Institute, Samuel E. Lux IV professor of hematology in the division of hematology/oncology at Children’s Hospital Boston, and professor of biological chemistry, molecular pharmacology, and pediatrics at Harvard Medical School;
Nancy E. Davidson, M.D., director of the University of Pittsburgh Cancer Institute, associate vice chancellor for cancer research and professor of medicine at University of Pittsburgh;
Mark E. Davis, Ph.D., Warren and Katharine Schlinger professor of chemical engineering at California Institute of Technology;
David L. Eaton, Ph.D., associate vice provost for research, professor of environmental health sciences, professor of public health genetics, and adjunct professor of medicinal chemistry in the School of Public Health at University of Washington;
Richard A. Gibbs, Ph.D., Wofford Cain professor in the department of molecular and human genetics and director of the Human Genome Sequencing Center at Baylor College of Medicine;
Joe W. Gray, Ph.D., Gordon Moore endowed chair in the department of biomedical engineering and director of the Center for Spatial Systems Biomedicine at Knight Cancer Institute at Oregon Health and Science University;
Michael Karin, Ph.D., distinguished professor of pharmacology and pathology in the School of Medicine at University of California, San Diego;
Jay S. Loeffler, M.D., Herman and Joan Suit professor in the department of radiation oncology at Harvard Medical School and chair of radiation oncology at Massachusetts General Hospital; and
Marc Tessier-Lavigne, Ph.D., president of Rockefeller University.
Current active members elect new members through a highly selective process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care and public health.
The IOM is unique in its structure as both an honorific membership organization and an advisory organization. Established in 1970 by the National Academy of Sciences, the IOM has become recognized as a national resource for independent, scientifically informed analysis and recommendations on health issues. Upon election, members make a commitment to volunteer their service on IOM committees, boards and other activities. Studies and initiatives during the past year include: a review of the long-term effects of traumatic brain injury among military personnel; an assessment of health effects due to lack of insurance; recommendations for comparative effectiveness research priorities; new guidelines for how much weight women should gain during pregnancy; a blueprint for American leadership in advancing global health; a strategy for preventing medical conflicts of interest; and a series of meetings on improving health care value through evidence-based medicine.
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 laboratory, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards to young investigators, and it also funds cutting-edge research projects conducted by senior researchers. The AACR has numerous fruitful collaborations with organizations and foundations in the U.S. and abroad, and functions as the Scientific Partner of Stand Up To Cancer, a charitable initiative that supports groundbreaking research aimed at getting new cancer treatments to patients in an accelerated time frame. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care, and Educational Workshops are held for the training of young cancer investigators. The AACR publishes seven major peer-reviewed journals: Cancer Discovery; Cancer Research; Clinical Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Prevention Research. In 2010, AACR journals received 20 percent of the total number of citations given to oncology journals. The AACR also publishes Cancer Today, a magazine for cancer patients, survivors and their caregivers, which provides practical knowledge and new hope for cancer survivors. A major goal of the AACR is to educate the general public and policymakers about the value of cancer research in improving public health, the vital importance of increases in sustained funding for cancer research and biomedical science, and the need for national policies that foster innovation and the acceleration of progress against the 200 diseases we call cancer.